Filtered By:
Drug: Avastin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 6276 results found since Jan 2013.

Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans Endothelium
In this study, we test the hypothesis that circulating vascular endothelial growth factor at physiological concentrations is essential to preserve normal endothelial control of vasomotor tone. In 7 healthy male volunteers, infusion of bevacizumab (monoclonal vascular endothelial growth factor antibody) into the brachial artery for 15 minutes (144 μg/dL forearm volume per minute) did not affect forearm vasodilator tone as measured with venous occlusion strain gauge plethysmography. In a separate group of 12 male volunteers, a similar bevacizumab infusion reduced the vasodilator response to 2 dosages of acetylcholine from...
Source: Hypertension - April 17, 2013 Category: Cardiology Authors: Thijs, A. M. J., van Herpen, C. M. L., Sweep, F. C. G. J., Geurts-Moespot, A., Smits, P., van der Graaf, W. T. A., Rongen, G. A. Tags: Endothelium/vascular type/nitric oxide, Other Vascular biology Source Type: research

Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation
Objective: Although vascular endothelial growth factor inhibition (VEGFi) represents a major therapeutic advance in oncology, it is associated with hypertension and adverse vascular thrombotic events. Our objective was to determine whether VEGFi caused direct vascular dysfunction through increased endothelin-1 (ET-1) activity or impaired endothelial vasomotor or fibrinolytic function. Methods: Using forearm venous occlusion plethysmography, we measured forearm blood flow during intra-arterial infusions of bevacizumab (36–144 μg/dl forearm volume per minute) administered for 15–60 min in healthy volunteers (nâ...
Source: Journal of Hypertension - January 10, 2020 Category: Cardiology Tags: ORIGINAL PAPERS: Vascular damage Source Type: research

Vascular endothelial growth factor A (VEGF-A) decreases expression and secretion of pleiotrophin in a VEGF receptor-independent manner.
Abstract Vascular endothelial growth factor A (VEGF-A) is a key molecule in angiogenesis acting through VEGF receptors (VEGFRs), ανβ3 integrin, receptor protein tyrosine phosphatase beta/zeta (RPTPβ/ζ) and cell surface nucleolin (NCL). Pleiotrophin (PTN) stimulates endothelial cell migration and limits the angiogenic effects of VEGF-A165 to the levels of its own effect, possibly acting as a VEGF-A165 modifier. Since PTN and VEGF-A165 share receptors and actions on endothelial cells, in the present work we studied whether and how VEGF-A165 affects PTN expression or secretion. VEGF-A165 decreased PTN mRNA and p...
Source: Vascular Pharmacology - February 23, 2016 Category: Drugs & Pharmacology Authors: Poimenidi E, Theodoropoulou C, Koutsioumpa M, Skondra L, Droggiti E, van den Broek M, Koolwijk P, Papadimitriou E Tags: Vascul Pharmacol Source Type: research

Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours
r & U T Hacker
Source: British Journal of Cancer - February 3, 2015 Category: Cancer & Oncology Authors: O CoutelleL M SchiffmannM LiwschitzM BrunoldV GoedeM HallekH KashkarU T Hacker Tags: Angiopoietin-2 VEGF vascular normalisation basement membrane sleeves xenograft tumours bevacizumab Source Type: research

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
& O Coutelle
Source: British Journal of Cancer - February 27, 2017 Category: Cancer & Oncology Authors: L M Schiffmann M Brunold M Liwschitz V Goede S Loges M Wroblewski A Quaas H Alakus D Stippel C J Bruns M Hallek H Kashkar U T Hacker O Coutelle Tags: angiogenesis cancer microenvironment vascular normalisation extracellular matrix VEGF PDGF Source Type: research

The effect of chemotherapy type and timing among the other factors on patency of totally implantable vascular access devices in colorectal carcinoma
CONCLUSION: A major effect on catheter patency was detected by using the target-directed chemotherapy agent within 3 days, which should be considered in target-directed chemotherapy.PMID:34796758 | DOI:10.1177/11297298211059263
Source: The Journal of Vascular Access - November 19, 2021 Category: Surgery Authors: Bilgin Kadri Aribas Fatih Yildiz Tugba Uylar Ramazan Tiken Hale Aydin Ismail Akdulum Turgut Seber Emrah Caglar Burcu Savran Ozge Aribas Source Type: research

Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
CONCLUSIONS: Compared to no treatment, repeated intravitreal injection of anti-VEGF agents in eyes with CRVO macular oedema improved visual outcomes at six months. All agents were relatively well tolerated with a low incidence of adverse effects in the short term. Future trials should address the relative efficacy and safety of the anti-VEGF agents and other treatments, including intravitreal corticosteroids, for longer-term outcomes. PMID: 24788977 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - May 1, 2014 Category: Journals (General) Authors: Braithwaite T, Nanji AA, Lindsley K, Greenberg PB Tags: Cochrane Database Syst Rev Source Type: research

Anti-vascular endothelial growth factor for neovascular glaucoma
CONCLUSIONS: Anti-VEGFs as an adjunct to conventional treatment could help reduce IOP in NVG in the short term (four to six weeks), but there is no evidence that this is likely in the longer term. Currently available evidence regarding the short- and long-term effectiveness and safety of anti-VEGFs in achieving control of IOP, visual acuity, and complete regression of new iris vessels in NVG is insufficient. More research is needed to investigate the effect of these medications compared with, or in addition to, conventional surgical or medical treatment in achieving these outcomes in NVG.PMID:37010901 | PMC:PMC10069372 | D...
Source: Cochrane Database of Systematic Reviews - April 3, 2023 Category: General Medicine Authors: Thanitsara Rittiphairoj Gloria Roberti Manuele Michelessi Source Type: research

Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
CONCLUSIONS: The available RCT evidence suggests that repeated treatment of non-ischaemic MO secondary to BRVO with the anti-VEGF agent ranibizumab may improve clinical and visual outcomes at six and 12 months. However, the frequency of re-treatment has not yet been determined and the impact of prior or combined treatment with laser photocoagulation on the primary outcome is unclear. Results from ongoing studies should assess not only treatment efficacy but also, the number of injections needed for maintenance and long-term safety and the effect of any prior treatment. PMID: 23440840 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - March 2, 2013 Category: Journals (General) Authors: Mitry D, Bunce C, Charteris D Tags: Cochrane Database Syst Rev Source Type: research

Anti-vascular endothelial growth factor for neovascular glaucoma
CONCLUSIONS: Anti-VEGFs as an adjunct to conventional treatment could help reduce IOP in NVG in the short term (four to six weeks), but there is no evidence that this is likely in the longer term. Currently available evidence regarding the short- and long-term effectiveness and safety of anti-VEGFs in achieving control of IOP, visual acuity, and complete regression of new iris vessels in NVG is insufficient. More research is needed to investigate the effect of these medications compared with, or in addition to, conventional surgical or medical treatment in achieving these outcomes in NVG.PMID:37010901 | DOI:10.1002/14651858.CD007920.pub4
Source: Cochrane Database of Systematic Reviews - April 3, 2023 Category: General Medicine Authors: Thanitsara Rittiphairoj Gloria Roberti Manuele Michelessi Source Type: research

Anti-vascular endothelial growth factor for neovascular glaucoma.
CONCLUSIONS: Currently available evidence is insufficient to evaluate the effectiveness of anti-VEGF treatments, such as intravitreal ranibizumab or bevacizumab, as an adjunct to conventional treatment in lowering IOP in NVG. Well designed RCTs are needed to address this issue, particularly trials that evaluate long-term (at least six months) benefits and risks since the effects of anti-VEGF agents may be short-term only. An RCT comparing anti-VEGF agents with no anti-VEGF agents taking into account the need for co-interventions, such as panretinal photocoagulation (PRP), glaucoma shunt procedures, cyclodestructive procedu...
Source: Cochrane Database of Systematic Reviews - October 2, 2013 Category: Journals (General) Authors: Simha A, Braganza A, Abraham L, Samuel P, Lindsley K Tags: Cochrane Database Syst Rev Source Type: research